Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.40 |
| ▸ | KDM5A | P29375 | 4/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 5/20 | 0.37 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31271923 | 1.00 | DNM1 (0.40) | DNM1KDM4CKDM5APHF8CES2 | |
| SCHEMBL31271866 | 0.86 | CES2 (0.39) | KDM4CKDM5APHF8CES2MAPT | |
| SCHEMBL31272298 | 0.86 | CES2 (0.39) | KDM4CKDM5APHF8CES2MAPT | |
| SCHEMBL26486042 | 0.82 | DNM1 (0.58) | DNM1KDM4CKDM5APHF8EPHX2 | |
| SCHEMBL31271676 | 0.81 | MAPT (0.38) | DNM1KDM4CKDM5APHF8MAPT | |
| SCHEMBL8483319 | 0.78 | DNM1 (0.54) | DNM1KDM4CKDM5APHF8KDM4A | |
| SCHEMBL13571403 | 0.78 | DNM1 (0.54) | DNM1KDM4CKDM5APHF8KDM4A | |
| SCHEMBL25129667 | 0.78 | CES2 (0.52) | KDM4CKDM5APHF8CES2 | |
| SCHEMBL25129665 | 0.78 | CES2 (0.52) | KDM4CKDM5APHF8CES2 | |
| SCHEMBL9694578 | 0.78 | CES2 (0.52) | KDM4CKDM5APHF8CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727915-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2026-04-22 | — | — | EP | disclosed |
| US-20240423914-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2024259315-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423914-A1 | AMIDE CONTAINING LIPIDS | PHOSPHO1, SGMS1, SGMS2 | DNM1 604/4885KDM4C 3921/4885KDM5A 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.